There are two types of cells in the prostate: basal and luminal cells. Whether cancer initially starts in a basal cell or a luminal cell, it almost always takes on the properties of luminal cells as the cancer grows. But over time, and in response to treatment, some tumors become less l...
The article provides an overview of the use of hormone ablation therapy for primary, neoadjuvant, or advanced prostate cancer management. It also examines adverse events that can arise in the exercise of this prostate cancer treatment and the vital role that nurses can play for its success. It ...
In breast cancer, and to a lesser extent in endometrial cancer, the concentrations of receptors for estrogen and progestin in the malignant tissue are regarded as prognostic factors in early disease, and as predictive factors for the value of endocrine treatment for patients with advanced disease (...
Effective alternatives to HRT are available for the treatment of menopausal symptoms associated with endocrine therapy Safe and effective options can be offered to patients with breast cancer who require hormonal manipulation in order to proceed with fertility preservation techniquesAbstract...
There is no high level clinical evidence for treatment selection among these choices based on biological drivers of clinical disease. In August 2020, the Prostate Cancer Foundation convened a working group to meet and discuss biomarkers for hormone-sensitive prostate cancer, the proceedings of which ...
which represents a well-accepted tumour model for castration resistant prostate cancer26with respect to its sensitivity to current treatments,i.e. exhibiting tumour growth inhibitory effects after treatment with docetaxel27and its metastatic profile. The used cell line bears an intrinsic luciferase reporte...
Based on these mechanisms and models, this review proposes that the combination of multiple therapy strategies such as agonists/antagonists of SHRs plus endocrine therapy and the adoption of the latest sequencing technologies are expected to improve the efficacy of ER positive breast cancer treatment....
Although, glitazones have achieved clinical success for the treatment of diabetes, troglitazone (Rezulin®) and rosiglitazone (Avandia®) were withdrawn from the clinical practice in 2000 and 2010 due to severe hepatic and cardiac toxicity respectively.79 Recently in 2013, in light ...
Although ER and PR are generally considered to be static rather than dynamic tumor markers, some variance can occur depending on the disease progression and hormone treatment. Suspected biological cancer progression or second primary breast cancer may warrant the evaluation of another tumor sample for ...
Prostate cancer treatment; Salivary gland tumors - for treatment of recurrent, unresectable, or metastatic salivary gland tumors as a single agent when the tumor is androgen receptor positive; Inhibition of premature luteinizing hormone (LH) surge in a member undergoing ovulation induction or assisted ...